Sanofi Pledges $125M to Denali in Pact for Neuro, Inflammation Drugs

Sanofi sees potential in two early-stage Denali Therapeutics drugs as a way to reduce inflammation in the brain and throughout the body, and the two companies are teaming up to develop the compounds for tough-to-treat diseases including Alzheimer’s.